Abstract
The introduction of the drug-eluting stent (DES) has revolutionized the field of interventional cardiology during the past decade. Initial pivotal randomized clinical trials showed a large reduction in restenosis rates and the need for repeat intervention with DES compared with bare-metal stents. The three main components of a DES are 1) the stent platform, 2) a coating facilitating elution of the drug (mostly a polymer), and 3) a antiproliferative/anti-inflammatory drug. Currently, two classes of drugs are widely used in DES, Taxanes, including its best-known member Paclitaxel, and Rapamycins, which include Sirolimus and its analogues such as Everolimus, Zotarolimus and Biolimus A9. The first DES to receive United States Food and Drug Administration approval was the Sirolimus-eluting stent. Recently, two other stent types eluting a Sirolimus-analogue were approved; the Zotarolimus-eluting stent and the Everolimuseluting stent. Biolimus A9-eluting stents, using biodegradable polymers, are currently approved and marketed outside of the United States. This review article focusses on the clinical studies that have been performed with DES eluting Sirolimus or its analogues.
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Zotarolimus, Everolimus, Biolimus, drug-eluting stent (DES), restenosis rates, Taxanes, Paclitaxel, Rapamycins, Everolimus, Zotarolimus, Everolimuseluting, biodegradable polymers
Current Pharmaceutical Design
Title: Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems
Volume: 16 Issue: 36
Author(s): Bimmer E. Claessen, Jose P.S. Henriques and George D. Dangas
Affiliation:
Keywords: Drug-eluting stents, Sirolimus, Rapamycin derivatives, Zotarolimus, Everolimus, Biolimus, drug-eluting stent (DES), restenosis rates, Taxanes, Paclitaxel, Rapamycins, Everolimus, Zotarolimus, Everolimuseluting, biodegradable polymers
Abstract: The introduction of the drug-eluting stent (DES) has revolutionized the field of interventional cardiology during the past decade. Initial pivotal randomized clinical trials showed a large reduction in restenosis rates and the need for repeat intervention with DES compared with bare-metal stents. The three main components of a DES are 1) the stent platform, 2) a coating facilitating elution of the drug (mostly a polymer), and 3) a antiproliferative/anti-inflammatory drug. Currently, two classes of drugs are widely used in DES, Taxanes, including its best-known member Paclitaxel, and Rapamycins, which include Sirolimus and its analogues such as Everolimus, Zotarolimus and Biolimus A9. The first DES to receive United States Food and Drug Administration approval was the Sirolimus-eluting stent. Recently, two other stent types eluting a Sirolimus-analogue were approved; the Zotarolimus-eluting stent and the Everolimuseluting stent. Biolimus A9-eluting stents, using biodegradable polymers, are currently approved and marketed outside of the United States. This review article focusses on the clinical studies that have been performed with DES eluting Sirolimus or its analogues.
Export Options
About this article
Cite this article as:
E. Claessen Bimmer, P.S. Henriques Jose and D. Dangas George, Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454941
DOI https://dx.doi.org/10.2174/138161210794454941 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
Current Pharmaceutical Design Pioglitazone Therapy Decreases Bone Mass Density and Increases Fat Mass: A Meta-Analysis
Current Pharmaceutical Design Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Human Platelet-Derived Growth Factor Enhances Healing of Ulcers Situated on Non-Foot Sites in Diabetics. A Pilot Study
Current Drug Therapy Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy
Current Diabetes Reviews Role of Ischemia Modified Albumin Serum Levels as an Oxidative Stress Marker in Children with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Tombstoning ST-Elevation Myocardial Infarction
Current Cardiology Reviews Management of Type 2 Diabetes: More Evidence is Required to Address the Clinical and Contextual Facets
Current Diabetes Reviews Pneumonia in the Elderly
Current Respiratory Medicine Reviews Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches
Current Pharmaceutical Design Liraglutide-A Novel GLP-1 Analogue
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Opioid Dependency and Myocardial Infarction: A Systematic Review and Meta-Analysis
Current Reviews in Clinical and Experimental Pharmacology Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors
Current Medicinal Chemistry Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Stroke Prevention in Atrial Fibrillation: Concepts and Controversies
Current Cardiology Reviews Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Metabolomics Reveals Hyperlipidemic Biomarkers and Antihyperlipidemic Effect of Poria cocos
Current Metabolomics